Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Parkinson's disease (PD) is the second most common neurodegenerative disease after
Alzheimer's. PD is considered a multifactorial disorder that results, in most cases, from the …

Parkinson disease (PD) is the second most common age-related neurodegenerative
condition diagnosed in North America. We recently demonstrated, using multiple …

Parkinson's disease (PD), following Alzheimer's disease, is the second‐most common
neurodegenerative disorder in the United States. A lack of treatment options for changing …

Dementia is one of the most common and important aspects of Parkinson's disease and has
consequences for patients and caregivers, and has health-related costs. Mild cognitive …

This study was undertaken to determine the prevalence and correlates of cognitive
impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with …

6 Guidelines((“guideline”[pt] OR “practice guideline”[pt] OR “health planning guidelines”[mh]
OR “consensus development conference”[pt] OR “consensus development conference …

The aggregation of α-synuclein (αSyn) is considered a key pathophysiological feature of
certain neurodegenerative disorders, collectively termed synucleinopathies. Given that a …

Apolipoprotein E (APOE) ε4 genotype is associated with increased risk of dementia in
Parkinson's disease (PD), but the mechanism is not clear, because patients often have a …

Objective To examine mortality and associated risk factors, including possible effects of mild
cognitive impairment, imaging, and CSF abnormalities, in a community-based population …